Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
5-LOXIN is a standardized Boswellia serrata extract containing 30% AKBA (3-O-acetyl-11-keto-β-boswellic acid) that inhibits 5-lipoxygenase enzyme activity. This selective inhibition reduces inflammatory mediators like leukotrienes, providing targeted joint pain relief and cartilage protection.
Reported Benefits (Provisional)
Origin & History
5-LOXIN is a branded extract of Boswellia serrata, standardized to contain 30% acetyl-11-keto-beta-boswellic acid (AKBA). It is produced through a specialized extraction process that concentrates the active components.
Research Narrative (Provisional)
Clinical studies have demonstrated that 5-LOXIN effectively reduces inflammation and joint pain. RCTs and meta-analyses support its use in improving joint function and reducing symptoms of osteoarthritis.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
5-LOXIN is a standardized Boswellia serrata extract concentrated to 30% acetyl-11-keto-β-boswellic acid (AKBA), its most pharmacologically active boswellic acid. Typical clinical doses range from 100–250 mg/day, delivering approximately 30–75 mg of AKBA per serving. Additional boswellic acids present include β-boswellic acid, 11-keto-β-boswellic acid (KBA), and α-boswellic acid at varying concentrations. AKBA demonstrates selective, non-redox inhibition of 5-lipoxygenase (5-LOX) with an IC50 of approximately 1.5 µM. Bioavailability of boswellic acids is notably enhanced when taken with a high-fat meal (up to 2-fold increase in Cmax), as these are lipophilic triterpenic acids. The extract contains negligible macronutrients (protein, carbohydrates, fat) in functional doses, and does not contribute meaningfully to vitamin or mineral intake. Phospholipid-complexed formulations (e.g., phytosome delivery) can further enhance AKBA absorption by improving gut wall permeability.
Reported Mechanism (Provisional)
5-LOXIN's primary bioactive compound AKBA selectively inhibits 5-lipoxygenase (5-LOX) enzyme, blocking the conversion of arachidonic acid to inflammatory leukotrienes. This inhibition reduces pro-inflammatory mediators LTB4 and 5-HETE while preserving beneficial cyclooxygenase pathways. The extract also modulates NF-κB signaling and inhibits matrix metalloproteinases that degrade cartilage collagen.
Clinical Narrative (Provisional)
Human trials with 5-LOXIN have shown significant improvements in joint function and pain reduction. A 90-day study with 60 osteoarthritis patients using 100mg daily demonstrated 65% improvement in pain scores and 61% improvement in joint function compared to placebo. Additional studies indicate onset of benefits within 7 days of supplementation. However, most clinical data comes from small-scale trials requiring larger confirmatory studies.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.